A recent study indicates that eating kimchi may help lower cholesterol levels, particularly in adults aged 40 and older. The research highlights the potential benefits of consuming one to three servings of kimchi daily, with variations in effects observed between men and women.
A recent study conducted in Chennai reveals that individuals with a genetic predisposition to high LDL cholesterol can significantly improve their cholesterol levels through dieta…
Rhubarb, often overlooked in grocery stores, is gaining attention for its potential health benefits, particularly related to cholesterol management and digestion. Recent studies i…
Dietitian Natalie Rizzo highlights the importance of plant-based proteins rich in soluble fiber for lowering cholesterol levels. Beans, particularly navy beans, and lentils are re…
Recent research indicates that a gut-derived molecule, imidazole propionate (ImP), may elevate the risk of Alzheimer's disease and accelerate cognitive decline. This study highlig…
Pomegranates are gaining recognition for their potential protective effects on liver health, particularly against conditions like fatty liver disease. Rich in polyphenols and anti…
A recent meta-analysis involving 1,357 adults with overweight or obesity found that high-quality protein supplementation is associated with small but statistically significant red…
A recent study indicates that urolithin A, a compound produced by gut bacteria from pomegranate polyphenols, may help reduce plaque buildup in arteries. The research showed that m…
Potatoes, often misunderstood in the context of nutrition, offer a range of essential nutrients, including vitamins and minerals. Experts emphasize their potential benefits when p…
Researchers at the Medical University of South Carolina are investigating a new approach to managing cholesterol, focusing on preventing its production rather than enhancing its c…
The experimental gene-editing drug VERVE-102, developed by Eli Lilly, has demonstrated the potential to reduce LDL cholesterol levels by up to 62% in early trials. This therapy ai…
A recent trial failure by Novartis has adversely affected the entire Lp(a) drug class, with Amgen experiencing a significant drop in stock value despite its own positive trial res…